恒瑞医药：SHR-3045注射液获得药物临床试验批准

Group 1 - The core point of the article is that 恒瑞医药 has received approval from the National Medical Products Administration for clinical trials of SHR-3045 injection, a self-developed biological product aimed at treating rheumatoid arthritis [1] - SHR-3045 injection is expected to suppress immune cell function, reduce inflammation, and improve clinical symptoms during rheumatoid arthritis treatment [1] - Currently, there are no similar drugs approved for market in both domestic and international markets [1] Group 2 - The total research and development investment for the SHR-3045 injection project has reached approximately 35.54 million yuan [1]